

RealRate

PHARMACEUTICAL 2017

## Esperion Therapeutics Inc. Rank 26 of 292





**ESPERION**<sup>®</sup>



PHARMACEUTICAL 2017



## RealRate

Esperion Therapeutics Inc. Rank 26 of 292

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 243%, being 240% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	213,577
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,589
Liabilities, Non-Current	1,022
Other Assets	30,962
Other Compr. Net Income	310
Other Expenses	376
Other Liabilities	0
Other Net Income	1,548
Other Revenues	0
Property and Equipment	674
Research and Development	57,868
Selling, General and Administrative Expense	18,282

Output Variable	Value in 1000 USD
Assets	245,213
Liabilities	16,611
Expenses	76,526
Revenues	0
Stockholders Equity	228,602
Net Income	-74,978
Comprehensive Net Income	-74,823
Economic Capital Ratio	243%

